Reviews/Perioperative Immunotherapy Solid Tumours/Perioperative nivolumab event-free survival in non-small cell lung cancer
Nsclc · PERIO-NSCLC-01 · v2
One large, well-conducted randomised trial [3] tested exactly what the claim describes: giving nivolumab with chemotherapy before and after surgery versus chemotherapy alone, in patients with operable lung cancer. In that trial, far more patients were free of cancer returning or progressing at 18 months on the nivolumab regimen (70.2% versus 50.0%) [3]. The same finding held in the trial's subgroups [10][11][24] and pointed the same way in separate trials of the same drug given only before surgery [15] and of similar drugs given before and after surgery [1][2]. Nothing in the corpus pointed the other way. The main reasons the panel did not place this at the ceiling are that only this one trial tests the precise before-and-after nivolumab regimen, it was reported early (at an interim look), and it does not yet show whether patients live longer overall.
The corpus contains one phase 3 double-blind randomised trial, CheckMate 77T [3], that matches the claim's regimen, comparator, endpoint and population and shows an 18-month event-free survival of 70.2% versus 50.0% (hazard ratio 0.58) [3]. This is reinforced within the same trial by the N2 subgroup (HR 0.46) [10], the Japanese subpopulation (HR 0.46) [11] and the primary-outcome abstract (HR 0.58, P=0.00025) [24]. Independent trials agree in direction: NADIM II used the same perioperative nivolumab regimen with a progression-free survival HR of 0.47 [2], KEYNOTE-671 tested the same perioperative design with pembrolizumab (EFS HR 0.58) [1], and CheckMate 816 tested neoadjuvant-only nivolumab plus chemotherapy (EFS HR 0.63) [15]. Because event-free survival is directly measured rather than inferred from a pathological surrogate, there is no surrogate-endpoint inference. The contested point: The evidence does not divide on direction; every eligible line favours the regimen. The only live point is weight: the exact perioperative-nivolumab regimen against chemotherapy with EFS as primary endpoint rests on a single interim-stage trial [3], while [2] used a different endpoint and stage III only and [15] gave nivolumab before surgery only.
All 29 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Perioperative Immunotherapy Solid Tumours, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The exact perioperative-nivolumab regimen vs chemo with EFS as primary endpoint is tested in only ONE phase 3 trial (CheckMate 77T [3]), reported at a prespecified interim analysis (median follow-up ~25 months). NADIM II [2] used a pCR primary with PFS secondary and stage III only; CheckMate 816 [15] is neoadjuvant-only. The claim therefore rests substantially on a single immature pivotal trial.
The claim specifies stage II-IIIA, but the pivotal trial enrolled IIA-IIIB and the corpus provides no isolated resectable-stage-II EFS estimate; stage coverage is adequate but the stage-II margin is inferred from a broader population.
Where it remains uncertain. The precise perioperative-nivolumab regimen is tested in only one trial [3], at a prespecified interim analysis, with no overall-survival result reported in this corpus.
Aleatory
The pivotal result [3] is from a prespecified interim analysis at median follow-up 25.4 months; the point estimate will move as events accrue.
Epistemic
No overall-survival result for the perioperative nivolumab regimen is reported in this corpus [3]; durability on a hard outcome is not yet demonstrated here.
Inferential
The claim specifies stage II-IIIA but the trial enrolled IIA-IIIB [3]; the stage-II benefit is read off a broader population, with no isolated stage-II EFS estimate in the corpus.
The load-bearing papers from a corpus of 29, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Independent phase 3 RCT of the same perioperative design with a different PD-1 agent — class-level corroboration of the EFS effect.
“Event-free survival at 24 months was 62.4% in the pembrolizumab group and 40.6% in the placebo group (hazard ratio for progression, recurrence, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.72; P<0.001)”
Panel auditInternal validity: high · scope of inference: Perioperative pembrolizumab plus chemotherapy vs chemotherapy in resectable stage II/IIIA/IIIB(N2) NSCLC.Key limitations: different PD-1 agent (pembrolizumab) · interim analysis
Independent RCT of near-identical perioperative nivolumab regimen; PFS benefit corroborates direction (stage III, PFS endpoint).
“Kaplan-Meier estimates of progression-free survival at 24 months were 67.2% in the experimental group and 40.9% in the control group (hazard ratio for disease progression, disease recurrence, or death, 0.47; 95% CI, 0.25 to 0.88)”
Panel auditInternal validity: medium · scope of inference: Resectable stage IIIA/IIIB NSCLC treated with perioperative nivolumab plus chemotherapy.Key limitations: small open-label phase 2 · endpoint is PFS not EFS · stage III not II-IIIA · survival a secondary endpoint
Pivotal phase 3 RCT of the exact perioperative nivolumab regimen vs chemo with EFS primary endpoint in resectable NSCLC — directly establishes the claim.
“Perioperative treatment with nivolumab resulted in significantly longer event-free survival than chemotherapy in patients with resectable NSCLC.”
Panel auditInternal validity: high · scope of inference: Resectable stage IIA to IIIB NSCLC treated with perioperative nivolumab plus chemotherapy.Key limitations: prespecified interim analysis · stage range extends to IIIB beyond claim window
This analysis reports OS as its result; EFS is mentioned only as prior background, not re-analysed here.
Panel auditInternal validity: high · scope of inference: Overall survival of neoadjuvant nivolumab plus chemotherapy in resectable stage IB-IIIA NSCLC.Key limitations: reports OS not EFS · neoadjuvant only · includes stage IB
4 of 29 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A positive, statistically significant phase 3 RCT of the precise regimen and endpoint, concordant across every eligible independent line of evidence, supports an Established verdict, held just below ceiling because it rests on a single interim-stage pivotal trial.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Mature overall survival for the perioperative regimen. The corpus reports no OS for CheckMate 77T [3]; durability on a hard outcome is the main open question for this regimen. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Report the prespecified final overall-survival analysis of CheckMate 77T [3] at full maturity.
Open question: Does perioperative nivolumab plus chemotherapy improve overall survival, not only event-free survival, in resectable NSCLC? Why it is still open: CheckMate 77T [3] reports EFS at interim but no overall-survival result appears in this corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19